SHIFT Newsroom · UK

Strengthened Warnings for GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists

The MHRA has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.

By SHIFT AI Newsroom · Published 10 September 2026

How we prepare and check newsroom articles · Report a correction

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines.

SHIFT’s take

What we think this could mean for you, and what remains uncertain.

This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines, as it highlights the potential risk of acute pancreatitis, including necrotising and fatal cases.

Known facts

The MHRA has issued strengthened warnings on acute pancreatitis for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.

Sources and evidence

MHRA — Source date: 29 January 2026

← Back to SHIFT Newsroom